secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001140361-25-016660
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ATAI Life Sciences CBO Sahil Kirpekar departs; separation and consulting agreements finalized
--------------------------------------------------------------------------------

- Sahil Kirpekar terminated as Chief Business Officer effective April 2, 2025; separation agreement signed April 24.
- Separation provides up to $5,000 legal fee reimbursement, extended option exercise to Aug 14, 2025, $3,400 learning costs, $12,000 relocation, company computer retention.
- Consulting agreement effective April 3 for transitional BD support through Dec 31, 2025; allows vesting of 50% of unvested options from Mar 2023 and Mar 2024 grants.
- No replacement named; Kirpekar continues as consultant for business development transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/0001140361-25-016660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/ef20048125_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-016660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer